1,330 words · Editorial
Two Molecules, Four Brands: The GLP-1 Map That Ends the Confusion
Ozempic, Wegovy, Mounjaro, Zepbound. Most comparisons between them are unanswerable — because they're comparing across two different axes at once.
Published
Key takeaways
- There are two active molecules: semaglutide, sold as Ozempic for type 2 diabetes and Wegovy for weight management, and tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management.
- Comparisons across the same molecule (Ozempic vs Wegovy) are about indication and dose, not about which drug works better.
- Diagonal comparisons like Zepbound vs Ozempic pit different molecules and different purposes against each other — any confident verdict there answers a question nobody has.
- The brand on your prescription, not the molecule inside, decides your coverage and your price.
- Head-to-head trial data exists for specific pairings — SURMOUNT-5 for tirzepatide vs semaglutide in obesity, SURPASS-2 for tirzepatide vs semaglutide in type 2 diabetes.
Someone asks whether Zepbound is better than Ozempic. Someone else asks about Mounjaro versus Wegovy. Both questions get long answers online, and both answers are structurally confused — because those pairings don't compare like with like.
Here is the entire map. It takes thirty seconds to learn and it resolves most of the category's confusion permanently.
The grid
There are two active drugs. Each is sold under one brand for type 2 diabetes and another brand for weight management.
Semaglutide
- Diabetes: Ozempic (weekly injection) and Rybelsus (daily pill)
- Weight management: Wegovy
Tirzepatide
- Diabetes: Mounjaro
- Weight management: Zepbound
That's it. Four familiar brand names, two molecules, two purposes.
Why this fixes the confusing comparisons
Once you see the grid, you can classify any comparison instantly:
Compare down a column — same purpose, different molecule. These are real questions with real answers. Zepbound vs Wegovy is a legitimate weight-management comparison. Ozempic vs Mounjaro is a legitimate diabetes comparison.
Compare across a row — same molecule, different brand. Also legitimate, but the answer is usually about indication and coverage rather than about the drug. Ozempic and Wegovy contain the same active molecule at different doses for different approved uses.
*Compare diagonally — different molecule and different purpose. This is Zepbound vs Ozempic and Mounjaro vs Wegovy*. There is no clean answer, because the two products aren't competing for the same job. Any confident-sounding verdict on these pairings is answering a question nobody actually has.
The two comparisons that have real head-to-head trials
Most drug comparisons you read are cross-trial guesswork: two separate studies, different populations, different protocols, results lined up side by side as though that were valid. Two GLP-1 comparisons are better than that, because the drugs were tested directly against each other.
Zepbound vs Wegovy — SURMOUNT-5 (New England Journal of Medicine, 2025). 751 adults with obesity but not diabetes, randomized to one drug or the other, each titrated to maximum tolerated dose, over 72 weeks. Average weight change: −20.2% with tirzepatide versus −13.7% with semaglutide.
Ozempic vs Mounjaro — SURPASS-2 (New England Journal of Medicine, 2021). In people with type 2 diabetes, tirzepatide lowered both A1C and body weight more than semaglutide.
Two caveats that headlines skip. In SURPASS-2 the comparator was semaglutide 1 mg — the maximum approved Ozempic dose at the time. Higher semaglutide doses were not tested in that trial, so it does not show tirzepatide beating semaglutide's strongest dosing. And in both trials, "more on average" is a group result: plenty of individuals do excellently on either drug.
There's also an honest trade-off inside the efficacy result. The drug that produced more weight loss and more A1C reduction also produced somewhat more gastrointestinal side effects. More effect and more nausea tend to travel together.
The part that actually decides your cost: brand, not molecule
Here's the thing most explanations miss entirely.
Insurers price products, not molecules.
The identical active drug can be routine covered care under its diabetes brand for someone with diabetes, and entirely uncovered under its weight brand for someone whose employer plan excludes weight-loss medication. Same molecule. Completely different bill.
Three consequences follow:
Your diagnosis drives coverage, not your preference. A diabetes brand prescribed for diabetes is ordinary covered care. The same molecule under the weight brand is covered only if your plan includes weight-loss drugs — and many employer plans carve them out entirely.
Asking for the diabetes brand "to save money" usually backfires. Prescribing Ozempic or Mounjaro for weight loss is off-label, and insurance almost never covers off-label weight-loss use. So you forfeit the coverage route precisely because the indication no longer matches — and end up paying cash for a drug whose on-label twin might have been coverable.
A non-weight indication can bypass a weight-loss exclusion. This is the genuinely useful one. Wegovy carries an FDA indication for cardiovascular risk reduction in adults with established heart disease and overweight or obesity (approved March 2024, based on the SELECT trial). Zepbound carries one for moderate-to-severe obstructive sleep apnea in adults with obesity.
Neither of those is a weight-loss indication. So coverage can be available through them even where a blanket weight-loss exclusion would otherwise block everything. People in that situation often conclude they have no route at all — and that conclusion can be wrong.
Whether it applies depends on your documented diagnosis and your specific plan language. It's a question for your prescriber and your plan, not a guarantee. But it's a question worth asking, and most people never do.
The practical differences nobody mentions until you're using it
Trial results decide which drug is more effective on average. These decide what living with it is like — and they differ more than most comparisons admit.
In-use storage. Once you start a pen: Ozempic up to 56 days. Mounjaro and Zepbound up to 21 days. That gap changes how you travel and what happens to a pen left out.
Missed dose windows. Roughly 5 days for semaglutide, 4 days for tirzepatide, after which you skip and resume on schedule.
Changing your dose day. Minimum gap of 48 hours for semaglutide, 72 hours for tirzepatide.
Devices. These have changed and are still changing — Wegovy now exists in more than one format, including a multi-dose pen, so older blanket statements about it are no longer safe. Check the pen you were actually dispensed.
Every one of those numbers is drug-specific and not interchangeable. Applying Ozempic's rule to Zepbound is a genuine error, and it's a common one. Always follow the instructions for the product in your hand.
Switching between them
Switching is common — usually driven by a formulary change, side effects, or an inadequate response.
The thing to understand: there is no published dose-equivalence table between the molecules. A semaglutide milligram figure and a tirzepatide milligram figure describe different things and cannot be matched number to number. In practice, switching means restarting titration on the new drug rather than jumping to a matching strength.
Two consequences worth planning for. Expect the early gastrointestinal side effects to return, even if you tolerated your previous drug perfectly — your body is adjusting to a new escalation. And confirm coverage for the new drug before stopping the old one, because an unapproved switch can leave you with a gap.
If the switch is being forced by your plan rather than chosen with your clinician, that's a formulary problem with its own remedy, not something you simply have to accept.
The short version
- Two molecules: semaglutide and tirzepatide
- Each has a diabetes brand and a weight-management brand
- Compare same-purpose products; diagonal comparisons have no clean answer
- Two comparisons have real head-to-head trials; most others are cross-trial guesswork
- Your brand and diagnosis decide your cost, not which molecule is objectively stronger
- Practical windows (storage, missed dose, dose-day changes) are drug-specific — never transfer them between products
I keep the detailed versions of these comparisons updated, with the trial data and the current cash prices: Zepbound vs Wegovy, Ozempic vs Mounjaro, and the full comparison index.
Sources
- SURMOUNT-5 — Tirzepatide versus Semaglutide in Obesity, New England Journal of Medicine, 2025: https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
- SURPASS-2 — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes, New England Journal of Medicine, 2021: https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
- SELECT — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, New England Journal of Medicine, 2023: https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- FDA prescribing information via DailyMed (semaglutide and tirzepatide products): https://dailymed.nlm.nih.gov/dailymed/
Checked July 2026. Indications, devices, and storage instructions change — the Instructions for Use in your box is the authority for your product.
Educational information, not medical advice. Which drug is appropriate for you is a decision for a licensed clinician.
Common questions about Two Molecules, Four Brands: The GLP-1 Map That Ends the Confusion
What is the difference between Ozempic and Wegovy?
They are the same molecule, semaglutide, sold under two brands for two approved purposes: Ozempic for type 2 diabetes and Wegovy for weight management, at different approved dosing. The practical difference is not effectiveness of the molecule but which indication your plan will cover and at what price.
Is Zepbound better than Ozempic?
That pairing compares a different molecule and a different purpose at once, so there is no clean answer. The comparisons with real trial evidence are same-purpose ones — tirzepatide versus semaglutide for obesity in SURMOUNT-5, and for type 2 diabetes in SURPASS-2.
Why does my insurance cover Mounjaro but not Zepbound?
Because coverage follows the brand and its labeled indication, not the molecule. Both are tirzepatide, but Mounjaro is labeled for type 2 diabetes while Zepbound is labeled for weight management, and many plans cover the diabetes indication while excluding or restricting weight-loss drugs.